









Markets
/
Stocks
/
nasdaq-eltx
/

Elicio Therapeutics Inc

ELTX

View Detailed Chart

9.980USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

159.37MMarket Cap

LossP/E TTM



Elicio Therapeutics Inc

9.980

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

+1.73%

5 Days

+0.91%

1 Month

+26.17%

6 Months

+11.88%

Year to Date

+95.69%

1 Year

+97.23%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 2 analysts

BUY

Current Rating

12.500

Target Price

25.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Elicio Therapeutics Inc

ELTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(2)

Neutral(2)

Buy(9)

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.015

Buy

RSI(14)

70.160

Buy

STOCH(KDJ)(9,3,3)

52.357

Neutral

ATR(14)

0.639

Low Volatility

CCI(14)

13.338

Neutral

Williams %R

35.484

Buy

TRIX(12,20)

1.014

Sell

StochRSI(14)

22.496

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

9.991

Sell

MA10

9.803

Buy

MA20

9.273

Buy

MA50

8.238

Buy

MA100

7.129

Buy

MA200

6.656

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.

Ticker SymbolELTX

CompanyElicio Therapeutics Inc

CEOMr. Robert (Bob) Connelly

Websitehttps://elicio.com/